Vimarsana
Biggest News Aggregation in the World

Oren Rom News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oren Rom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oren Rom Today - Breaking & Trending Today

Eating too much protein is bad for your arteries, and this amino acid is to blame - Vimarsana News

Eating too much protein is bad for your arteries, and this amino acid is to blame

University of Pittsburgh School of Medicine researchers discovered a molecular mechanism by which excessive dietary protein could increase atherosclerosis risk.

Dietary protein overload linked to increased atherosclerosis risk - Vimarsana News

Dietary protein overload linked to increased atherosclerosis risk

University of Pittsburgh School of Medicine researchers discovered a molecular mechanism by which excessive dietary protein could increase atherosclerosis risk.

Eating too much protein is bad for your arter - Vimarsana News

Eating too much protein is bad for your arter

<p>Consuming over 22% of dietary calories from protein can lead to increased activation of immune cells that play a role in atherosclerotic plaque formation and&nbsp;drive&nbsp;the disease risk, new study showed.</p>

New Drug Successfully Treats Fatty Liver Disease in Primate Model - Vimarsana News

New Drug Successfully Treats Fatty Liver Disease in Primate Model

Millions of people are affected by nonalcoholic steatohepatitis (NASH), which is a serious liver disease. A newly discovered amino acid compound has been found to successfully treat nonalcoholic fatty liver disease in non-human primates, representing a significant step towards the development of th

Potential drug treats fatty liver disease in - Vimarsana News

Potential drug treats fatty liver disease in

A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.